Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Specimen Handling 317Magnetic Resonance Spectroscopy 275pembrolizumab 268Carboplatin 190Cyclophosphamide 182Biopsy 175Cisplatin 164Gemcitabine 139Paclitaxel 137Bevacizumab 122fludarabine 119Nivolumab 115Radiotherapy 114Oxaliplatin 96venetoclax 94Fluorouracil 90Docetaxel 87Dexamethasone 86Capecitabine 86Drug Therapy 76Rituximab 74Pemetrexed 72Leucovorin 71durvalumab 70Radiosurgery 69Blood Specimen Collection 69Standard of Care 68Doxorubicin 64atezolizumab 62Radiation 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × efineptakin alfa × 90 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡